Sintx Technologies Inc (SINT)

$5.08

-0.03

(-0.59%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $4.98
    $5.14
    $5.08
    downward going graph

    1.97%

    Downside

    Day's Volatility :3.11%

    Upside

    1.17%

    downward going graph
  • $4.12
    $344.00
    $5.08
    downward going graph

    18.9%

    Downside

    52 Weeks Volatility :98.8%

    Upside

    98.52%

    downward going graph

Returns

PeriodSintx Technologies IncIndex (Russel 2000)
3 Months
-33.98%
0.0%
6 Months
-91.83%
0.0%
1 Year
-98.49%
0.0%
3 Years
-99.98%
-19.9%

Highlights

Market Capitalization
3.7M
Book Value
$38.86
Earnings Per Share (EPS)
-428.0
Wall Street Target Price
70.0
Profit Margin
0.0%
Operating Margin TTM
-425.62%
Return On Assets TTM
-36.98%
Return On Equity TTM
-68.43%
Revenue TTM
2.8M
Revenue Per Share TTM
74.16
Quarterly Revenue Growth YOY
27.500000000000004%
Gross Profit TTM
1.3M
EBITDA
-10.9M
Diluted Eps TTM
-428.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-152.51
EPS Estimate Next Year
-782.15
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Sintx Technologies Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1277.95%

Current $5.08
Target $70.00

Company Financials

FY18Y/Y Change
Revenue
95.0K
↓ 99.38%
Net Income
-8.7M
↓ 47.87%
Net Profit Margin
-9.1K%
↓ 8998.36%
FY19Y/Y Change
Revenue
689.0K
↑ 625.26%
Net Income
-4.8M
↓ 43.96%
Net Profit Margin
-703.77%
↑ 8403.6%
FY20Y/Y Change
Revenue
594.0K
↓ 13.79%
Net Income
-7.3M
↑ 50.81%
Net Profit Margin
-1.2K%
↓ 527.37%
FY21Y/Y Change
Revenue
606.0K
↑ 2.02%
Net Income
-9.8M
↑ 34.32%
Net Profit Margin
-1.6K%
↓ 389.82%
FY22Y/Y Change
Revenue
601.0K
↓ 0.83%
Net Income
-16.5M
↑ 67.86%
Net Profit Margin
-2.7K%
↓ 1122.63%
FY23Y/Y Change
Revenue
2.6M
↑ 337.1%
Net Income
-8.3M
↓ 49.91%
Net Profit Margin
-314.39%
↑ 2429.2%
Q4 FY22Q/Q Change
Revenue
247.0K
↑ 42.77%
Net Income
-8.4M
↑ 216.69%
Net Profit Margin
-3.4K%
↓ 1869.37%
Q1 FY23Q/Q Change
Revenue
240.0K
↓ 2.83%
Net Income
3.0M
↓ 135.31%
Net Profit Margin
1.2K%
↑ 4641.13%
Q2 FY23Q/Q Change
Revenue
235.0K
↓ 2.08%
Net Income
-2.5M
↓ 182.69%
Net Profit Margin
-1.0K%
↓ 2281.76%
Q3 FY23Q/Q Change
Revenue
678.0K
↑ 188.51%
Net Income
-3.2M
↑ 29.94%
Net Profit Margin
-470.5%
↑ 574.18%
Q4 FY23Q/Q Change
Revenue
902.0K
↑ 33.04%
Net Income
-2.3M
↓ 27.24%
Net Profit Margin
-257.32%
↑ 213.18%
Q1 FY24Q/Q Change
Revenue
687.0K
↓ 23.84%
Net Income
-886.0K
↓ 61.83%
Net Profit Margin
-128.97%
↑ 128.35%
FY18Y/Y Change
Total Assets
11.5M
↓ 56.15%
Total Liabilities
3.1M
↓ 73.79%
FY19Y/Y Change
Total Assets
9.1M
↓ 20.56%
Total Liabilities
3.9M
↑ 26.6%
FY20Y/Y Change
Total Assets
30.4M
↑ 232.86%
Total Liabilities
4.6M
↑ 17.69%
FY21Y/Y Change
Total Assets
21.8M
↓ 28.27%
Total Liabilities
4.1M
↓ 11.44%
FY22Y/Y Change
Total Assets
15.8M
↓ 27.78%
Total Liabilities
10.1M
↑ 144.87%
FY23Y/Y Change
Total Assets
15.4M
↓ 2.59%
Total Liabilities
6.6M
↓ 34.52%
Q4 FY22Q/Q Change
Total Assets
15.8M
↑ 8.31%
Total Liabilities
10.1M
↑ 95.59%
Q1 FY23Q/Q Change
Total Assets
22.7M
↑ 43.61%
Total Liabilities
6.7M
↓ 33.4%
Q2 FY23Q/Q Change
Total Assets
19.1M
↓ 15.69%
Total Liabilities
5.3M
↓ 21.18%
Q3 FY23Q/Q Change
Total Assets
15.5M
↓ 18.78%
Total Liabilities
4.8M
↓ 8.76%
Q4 FY23Q/Q Change
Total Assets
15.4M
↓ 0.95%
Total Liabilities
6.6M
↑ 36.7%
Q1 FY24Q/Q Change
Total Assets
17.6M
↑ 14.29%
Total Liabilities
7.6M
↑ 15.8%
FY18Y/Y Change
Operating Cash Flow
-9.3M
↑ 30.38%
Investing Cash Flow
-145.0K
↓ 87.25%
Financing Cash Flow
14.4M
↑ 347.65%
FY19Y/Y Change
Operating Cash Flow
-6.4M
↓ 31.16%
Investing Cash Flow
1.4M
↓ 1052.41%
Financing Cash Flow
1.4M
↓ 90.32%
FY20Y/Y Change
Operating Cash Flow
-9.1M
↑ 41.6%
Investing Cash Flow
1.8M
↑ 26.79%
Financing Cash Flow
30.9M
↑ 2118.44%
FY21Y/Y Change
Operating Cash Flow
-10.1M
↑ 11.19%
Investing Cash Flow
-1.7M
↓ 194.29%
Financing Cash Flow
705.0K
↓ 97.72%
FY22Y/Y Change
Operating Cash Flow
-10.3M
↑ 1.29%
Investing Cash Flow
-1.1M
↓ 33.31%
Financing Cash Flow
3.3M
↑ 373.19%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.1M
↓ 15.26%
Investing Cash Flow
-296.0K
↓ 41.96%
Financing Cash Flow
3.8M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.9M
↑ 133.85%
Investing Cash Flow
-236.0K
↓ 20.27%
Financing Cash Flow
11.5M
↑ 198.78%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.2M
↓ 34.31%
Investing Cash Flow
-98.0K
↓ 58.47%
Financing Cash Flow
-88.0K
↓ 100.77%
Q3 FY23Q/Q Change
Operating Cash Flow
-2.9M
↓ 8.87%
Investing Cash Flow
-105.0K
↑ 7.14%
Financing Cash Flow
-88.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Sintx Technologies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sintx Technologies Inc
Sintx Technologies Inc
-5.02%
-91.83%
-98.49%
-99.98%
-99.99%
Stryker Corporation
Stryker Corporation
0.78%
11.04%
17.54%
29.67%
60.01%
Boston Scientific Corp.
Boston Scientific Corp.
2.45%
31.16%
50.64%
78.74%
83.32%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-3.46%
20.0%
-4.76%
-20.06%
21.53%
Abbott Laboratories
Abbott Laboratories
-1.31%
-6.18%
-9.34%
-13.05%
17.3%
Medtronic Plc
Medtronic Plc
-2.02%
-6.28%
-10.55%
-38.0%
-22.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sintx Technologies Inc
Sintx Technologies Inc
NA
NA
NA
-152.51
-0.68
-0.37
NA
38.86
Stryker Corporation
Stryker Corporation
39.04
39.04
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.18
65.18
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.93
37.93
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.72
32.72
5.99
4.65
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.73
28.73
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sintx Technologies Inc
Sintx Technologies Inc
Buy
$3.7M
-99.99%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$130.4B
60.01%
39.04
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.0B
83.32%
65.18
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$53.0B
21.53%
37.93
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$180.4B
17.3%
32.72
13.65%
Medtronic Plc
Medtronic Plc
Buy
$101.7B
-22.41%
28.73
11.36%

Insights on Sintx Technologies Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 902.0K → 687.0K (in $), with an average decrease of 23.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -3.19M → -886.0K (in $), with an average increase of 99.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 50.6% return, outperforming this stock by 149.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 78.1% return, outperforming this stock by 178.1%

Institutional Holdings

  • Anson Funds Management LP

    0.78%
  • TWO SIGMA SECURITIES, LLC

    0.07%
  • Vanguard Group Inc

    0.04%
  • Geode Capital Management, LLC

    0.02%
  • HRT FINANCIAL LLC

    0.01%
  • State Street Corporation

    0.01%

Company Information

amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.

Organization
Sintx Technologies Inc
Employees
43
CEO
Dr. B. Sonny Bal J.D., M.B.A., M.D., Ph.D.
Industry
Health Technology

FAQs